D-0120 + uric acid lowering agent

**D-0120 + uric acid lowering agent** is an investigational combination therapy currently being studied for the management of hyperuricemia and gout. D-0120 is a novel, potent selective inhibitor of the urate transporter 1 (URAT1), under development by InventisBio. When combined with a uric acid lowering agent (such as xanthine oxidase inhibitors like allopurinol or febuxostat), the regimen aims to achieve deeper reductions in serum uric acid levels than monotherapy. Preclinical and phase 1 studies show D-0120 is well-tolerated and effectively lowers uric acid levels through URAT1 inhibition, and combination trials are ongoing to evaluate complementary urate-lowering effects and safety profile[1][2][3][4][5].